沙利度胺是什么？

沙利度胺是一种镇静催眠和多发性骨髓瘤的药物。这种药是兔和包括人类的灵长类动物的烈性 teratogen：严重的出生缺陷可能会导致在怀孕期间服用该药物。

在一些国家出售胺 1957 直到 1961 它何时退出市场后被发现是什么被称为"最大的近代医学悲剧之一"出生缺陷的原因, 从世界各地。它不知道确切的药物有多少世界各地受害者已，虽然估计为 20000 的范围由 10000。

自那时以来已发现胺是宝贵的治疗，大量的医疗条件，它被明再次在一些国家，尽管其使用仍有争议。沙利度胺悲剧导致更加严格测试正在和所需的药物农药之前他们可发牌。

进一步阅读

这篇文章是创作共用署名-相同方式共享授权许可。它使用材料从维基百科上"反应停"适应所有材料用从维基百科的文章是创新的知识共享署名-相同方式共享许可证的条款下提供。维基百科 ® 本身是维基媒体基金公司的注册的商标

Recent Thalidomide News

NEJM publishes results from Celgene’s REVLIMID phase III studies on MMCelgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly di...

Lenalidomide improves overall survival for patients with multiple myelomaData from the first large U.S. study assessing the effectiveness of long-term "maintenance" therapy with lenalidomide for patients with multiple myeloma show that the drug significantly improves the t...

Researchers discover connection between early humans and Neanderthals' genomeA striking discovery in the study of human genetics was the focus of the most-visited press release posted on EurekAlert! in 2011. Researchers found that part of the non-African human X chromosome cam...

Enrollment complete in Onyx Phase 3 ASPIRE trial for relapsed multiple myelomaOnyx Pharmaceuticals, Inc. today announced that it has reached the target enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide...

Cereblon protein now holds hope in fight against multiple myelomaResearch on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, say Mayo Clinic researchers who presented res...